Avantor (AVTR)
NYSE:AVTR
Top Page
Avantor
(NYSE:AVTR)
Select Model
Select Model
Rating:50Neutral
Price Target:
$8.00
▲(0.00% Upside)
Action:ReiteratedDate:02/12/26
The score is held back primarily by weakening fundamentals and uncertainty in the most recent financial snapshot, plus conservative 2026 guidance (continued organic revenue declines, margin contraction, and wide free-cash-flow range). Consistently positive cash flow and prior leverage improvement provide the main support, while bearish technicals and a negative P/E further pressure the overall rating.
Positive Factors
Consistent cash generation
Avantor’s persistent positive operating and free cash flow across years provides durable liquidity that funds operations, targeted investments and debt reduction without relying on volatile earnings. This cash resilience supports execution of turnaround programs and cushions near-term cyclical pressure.
Negative Factors
Organic revenue declines
Sustained organic revenue contraction and conservative 2026 organic guidance signal structural demand headwinds in lab distribution and bioprocessing end markets. Continued top-line erosion reduces operating leverage, limits ability to absorb fixed costs and constrains medium-term margin recovery unless growth drivers reaccelerate.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent cash generation
Avantor’s persistent positive operating and free cash flow across years provides durable liquidity that funds operations, targeted investments and debt reduction without relying on volatile earnings. This cash resilience supports execution of turnaround programs and cushions near-term cyclical pressure.
Read all positive factors
Avantor (AVTR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.46B
Dividend YieldN/A
Average Volume (3M)8.81M
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth-3.59%
EPS Growth-126.16%
CountryUS
Employees13,500
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.22
Shares Outstanding682,055,900
10 Day Avg. Volume6,101,652
30 Day Avg. Volume8,806,891
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.40
Price to Sales (P/S)1.19
P/FCF Ratio15.70
Enterprise Value/Market Cap1.66
Enterprise Value/Revenue1.38
Enterprise Value/Gross Profit4.22
Enterprise Value/Ebitda65.16
Forecast
1Y Price Target
$10.23Price Target Upside27.88% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)0.79
Revenue Forecast (FY)$6.49B
Avantor Business Overview & Revenue Model
Company Description
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers ma...
How the Company Makes Money
Avantor primarily makes money by selling products and services used throughout the life-sciences and advanced-technology workflows, generating revenue when customers purchase consumables, materials, and related services on a recurring basis. Key r...
Avantor Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much each business segment contributes to total revenue, indicating the company’s diversification and which segments are leading growth or facing headwinds.
Shows how much each business segment contributes to total revenue, indicating the company’s diversification and which segments are leading growth or facing headwinds.
Data provided by:
The Fly
The FlyAvantor Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 29, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: management has taken meaningful strategic actions (reorganization, VWR relaunch, Revival program) and achieved cash generation and cost savings, but near-term financials show declining organic revenue, margin pressure, operational bottlenecks and conservative guidance for 2026 (EPS down and guidance for EBITDA contraction). Execution of the Revival investments and operational fixes will be key to translating the strategic initiatives into sustainable top-line and margin recovery.Positive Updates
Go-to-Market Reorganization and VWR Relaunch
Management implemented a fundamental reorganization creating two business units (product-agnostic channel and channel-agnostic products) and recommitted to the VWR brand for distribution, aimed at clearer customer focus and faster decision-making; resegmentation effective in Q1 2026.
Negative Updates
Organic Revenue Declines
Q4 organic revenue declined 4% year-over-year (reported revenue $1.66B); full-year 2025 reported revenues were $6.552 billion, down 3% organically versus 2024. 2026 guidance calls for organic revenue growth of negative 2.5% to negative 0.5% (reported -1.5% to +0.5% after ~1% FX benefit).
Read all updates
Q4-2025 Updates
Positive
Negative
Go-to-Market Reorganization and VWR Relaunch
Management implemented a fundamental reorganization creating two business units (product-agnostic channel and channel-agnostic products) and recommitted to the VWR brand for distribution, aimed at clearer customer focus and faster decision-making; resegmentation effective in Q1 2026.
Read all positive updates
Company Guidance
Avantor guided 2026 organic revenue of -2.5% to -0.5% (FX expected to add ~1%, yielding reported growth of -1.5% to +0.5%), with VWR expected to somewhat outpace the Bioscience & MedTech product business; management sees adjusted EBITDA margins contracting ~100–150 bps (roughly in line with the margin level exiting 2025) and projects adjusted EPS of $0.77–$0.83 and free cash flow of $50M–$550M (back‑half weighted), assuming a ~22.5% tax rate, ~685M fully diluted shares and no share repurchases in 2026, with Q1 EPS pegged at $0.15–$0.16 and interest expense roughly flat to 2025; management reiterated a leverage reduction priority targeting sustainable net leverage below 3.0x from a 3.2x adjusted net leverage at year‑end 2025. For context, 2025 reported revenue was $6.552B, adjusted EBITDA $1.069B (16.3% margin), adjusted EPS $0.90, and 2025 free cash flow was $496M ($599M excluding transformation spend).Avantor Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
56
Neutral
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.55B | 6.78B | 6.97B | 7.51B | 7.39B |
| Gross Profit | 2.14B | 2.28B | 2.36B | 2.60B | 2.50B |
| EBITDA | 138.70M | 1.48B | 1.10B | 1.52B | 1.35B |
| Net Income | -530.20M | 711.50M | 321.10M | 686.50M | 572.60M |
Balance Sheet | |||||
| Total Assets | 11.79B | 12.11B | 12.97B | 13.46B | 13.90B |
| Cash, Cash Equivalents and Short-Term Investments | 365.40M | 261.90M | 262.90M | 372.90M | 301.70M |
| Total Debt | 3.95B | 4.06B | 5.54B | 6.29B | 7.02B |
| Total Liabilities | 6.23B | 6.16B | 7.72B | 8.61B | 9.70B |
| Stockholders Equity | 5.57B | 5.96B | 5.25B | 4.86B | 4.20B |
Cash Flow | |||||
| Free Cash Flow | 495.00M | 692.00M | 723.60M | 710.20M | 842.50M |
| Operating Cash Flow | 623.80M | 840.80M | 870.00M | 843.60M | 953.60M |
| Investing Cash Flow | -130.50M | 438.90M | -143.70M | -109.60M | -4.12B |
| Financing Cash Flow | -409.40M | -1.28B | -843.70M | -648.70M | 3.22B |
Avantor Technical Analysis
Neutral
8.00
Price Trends
8.93
Negative
10.25
Negative
11.67
Negative
Market Momentum
-0.27
Negative
45.31
Neutral
79.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTR, the sentiment is Neutral. The current price of 8 is above the 20-day moving average (MA) of 7.78, below the 50-day MA of 8.93, and below the 200-day MA of 11.67, indicating a neutral trend. The MACD of -0.27 indicates Negative momentum. The RSI at 45.31 is Neutral, neither overbought nor oversold. The STOCH value of 79.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AVTR.
Avantor Risk Analysis
Avantor disclosed 38 risk factors in its most recent earnings report. Avantor reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Avantor Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $8.47B | 15.45 | 8.09% | 5.33% | -3.33% | -19.59% | |
62 Neutral | $21.89B | 33.47 | 10.92% | ― | -10.07% | ― | |
61 Neutral | $15.45B | -6.32 | -15.50% | 2.88% | -5.32% | -1108.29% | |
57 Neutral | $20.91B | -32.60 | -5.13% | 1.10% | -23.92% | 90.47% | |
54 Neutral | $2.23B | -964.31 | -0.18% | 1.37% | 0.08% | -107.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $5.46B | -14.65 | -9.02% | ― | -3.59% | -126.16% |
* Healthcare Sector Average
AVTR
Avantor
8.00
-7.89
-49.65%
ALB
Albemarle
177.44
118.01
198.59%
EMN
Eastman Chemical
74.27
-3.39
-4.37%
KWR
Quaker Chemical
128.65
19.19
17.53%
SQM
Sociedad Quimica Y Minera SA
82.48
46.98
132.34%
WLK
Westlake Corporation
120.81
29.55
32.38%
Avantor Corporate Events
Executive/Board Changes
Avantor Announces CFO Resignation and Interim Finance Leadership
Neutral
Apr 1, 2026
Avantor announced that on March 26, 2026, Executive Vice President and Chief Financial Officer R. Brent Jones notified the company of his decision to resign to join a business outside the life sciences sector, triggering a transition period under ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.